Topic: Sanofi-Aventis SA
PARIS (Reuters) - French drugmaker Sanofi said on Saturday that its experimental multiple sclerosis drug Lemtrada worked better than an older drug sold by competitor Merck KGaA at keeping patients free from relapses.New data from a late-stage trial showed that 78 percent ...
SNY) announced today the results of a phase II study with teriflunomide a novel orally available immunomodulatory therapy for multiple sclerosis (MS). In this 24-week double blind, placebo-controlled, randomized, 3-arm multinational phase II clinical study conducted in 116 patients with relapsing-remitting MS, ...
Sanofi-Aventis says it will close its Kansas City drug plant by 2012Drug developer Sanofi-Aventis says it will close its Kansas City, Mo., plant by 2012, citing a decline in demand for products made at the site.The plant makes solid dose forms of ...
From Around the Web
Video Gallery
-
Mergers & Acquisitions: Sanofi-Aventis SA Bids $18...
"Sanofi-Aventis (NYSE:SNY) making a hostile $18.5 billion bid ...2010-10-04 -
Sanofi-Aventis Seeking Suitor For US Dermatology ...
Sanofi-Aventis SA (NYSE:SNY), France's largest drug maker, is ...2011-04-14 -
SRS (SA) 2009 Sanofi-Aventis Prize Winner
Dr David Muchuweti Abdominal Surgical Site Infection: Risk factors and ...2010-02-04
